BACKGROUND: In the United States, older adults have low rates of follow-up colonoscopy after a positive fecal occult blood test (FOBT) result. The long-term outcomes of these real world practices and their associated benefits and burdens are unknown. METHODS: Longitudinal cohort study of 212 patients 70 years or older with a positive FOBT result at 4 Veteran Affairs (VA) facilities in 2001 and followed up through 2008. We determined the frequency of downstream outcomes during the 7 years of follow-up, including procedures, colonoscopic findings, outcomes of treatment, complications, and mortality based on chart review and national VA and Medicare data. Net burden or benefit from screening and follow-up was determined according to each patient's life expectancy. Life expectancy was classified into 3 categories: best (age, 70-79 years and Charlson-Deyo comorbidity index [CCI], 0), average, and worst (age, 70-84 years and CCI, ≥4 or age, ≥85 years and CCI, ≥1). RESULTS: Fifty-six percent of patients received follow-up colonoscopy (118 of 212), which found 34 significant adenomas and 6 cancers. Ten percent experienced complications from colonoscopy or cancer treatment (12 of 118). Forty-six percent of those without follow-up colonoscopy died of other causes within 5 years of FOBT (43 of 94), while 3 died of colorectal cancer within 5 years. Eighty-seven percent of patients with worst life expectancy experienced a net burden from screening (26 of 30) as did 70% with average life expectancy (92 of 131) and 65% with best life expectancy (35 of 51) (P = .048 for trend). CONCLUSIONS: Over a 7-year period, older adults with best life expectancy were less likely to experience a net burden from current screening and follow-up practices than are those with worst life expectancy. The net burden could be decreased by better targeting FOBT screening and follow-up to healthy older adults.
BACKGROUND: In the United States, older adults have low rates of follow-up colonoscopy after a positive fecal occult blood test (FOBT) result. The long-term outcomes of these real world practices and their associated benefits and burdens are unknown. METHODS: Longitudinal cohort study of 212 patients 70 years or older with a positive FOBT result at 4 Veteran Affairs (VA) facilities in 2001 and followed up through 2008. We determined the frequency of downstream outcomes during the 7 years of follow-up, including procedures, colonoscopic findings, outcomes of treatment, complications, and mortality based on chart review and national VA and Medicare data. Net burden or benefit from screening and follow-up was determined according to each patient's life expectancy. Life expectancy was classified into 3 categories: best (age, 70-79 years and Charlson-Deyo comorbidity index [CCI], 0), average, and worst (age, 70-84 years and CCI, ≥4 or age, ≥85 years and CCI, ≥1). RESULTS: Fifty-six percent of patients received follow-up colonoscopy (118 of 212), which found 34 significant adenomas and 6 cancers. Ten percent experienced complications from colonoscopy or cancer treatment (12 of 118). Forty-six percent of those without follow-up colonoscopy died of other causes within 5 years of FOBT (43 of 94), while 3 died of colorectal cancer within 5 years. Eighty-seven percent of patients with worst life expectancy experienced a net burden from screening (26 of 30) as did 70% with average life expectancy (92 of 131) and 65% with best life expectancy (35 of 51) (P = .048 for trend). CONCLUSIONS: Over a 7-year period, older adults with best life expectancy were less likely to experience a net burden from current screening and follow-up practices than are those with worst life expectancy. The net burden could be decreased by better targeting FOBT screening and follow-up to healthy older adults.
Authors: Frank J Lukens; David S Loeb; Victor I Machicao; Sami R Achem; Michael F Picco Journal: Am J Gastroenterol Date: 2002-07 Impact factor: 10.864
Authors: H M Shields; M S Weiner; D R Henry; J A Lloyd; B J Ransil; D A Lamphier; D W Gallagher; D A Antonioli; B A Rosner Journal: Am J Gastroenterol Date: 2001-01 Impact factor: 10.864
Authors: Sidney J Winawer; Ann G Zauber; Robert H Fletcher; Jonathon S Stillman; Michael J O'Brien; Bernard Levin; Robert A Smith; David A Lieberman; Randall W Burt; Theodore R Levin; John H Bond; Durado Brooks; Tim Byers; Neil Hyman; Lynne Kirk; Alan Thorson; Clifford Simmang; David Johnson; Douglas K Rex Journal: Gastroenterology Date: 2006-05 Impact factor: 22.682
Authors: Charlotte M Carlson; Katharine A Kirby; Michele A Casadei; Melissa R Partin; Christine E Kistler; Louise C Walter Journal: Arch Intern Med Date: 2010-10-11
Authors: J D Hardcastle; J O Chamberlain; M H Robinson; S M Moss; S S Amar; T W Balfour; P D James; C M Mangham Journal: Lancet Date: 1996-11-30 Impact factor: 79.321
Authors: Durado D Brooks; Sidney J Winawer; Douglas K Rex; Ann G Zauber; Charles J Kahi; Robert A Smith; Bernard Levin; Richard Wender Journal: Am Fam Physician Date: 2008-04-01 Impact factor: 3.292
Authors: Nancy L Schoenborn; Jin Huang; Orla C Sheehan; Jennifer L Wolff; David L Roth; Cynthia M Boyd Journal: J Gen Intern Med Date: 2018-11-06 Impact factor: 5.128
Authors: Cynthia So; Katharine A Kirby; Kala Mehta; Richard M Hoffman; Adam A Powell; Stephen J Freedland; Brenda Sirovich; Elizabeth M Yano; Louise C Walter Journal: J Gen Intern Med Date: 2011-12-17 Impact factor: 5.128
Authors: Kathryn L Moore; Carmen L Lewis; Sheryl Zimmerman; Kimberly Ward; David Reed; Robert Rodriguez; Christine E Kistler Journal: J Am Geriatr Soc Date: 2014-02 Impact factor: 5.562
Authors: Carmen L Lewis; Denise Esserman; Christopher DeLeon; Michael P Pignone; Donald E Pathman; Carol Golin Journal: J Gen Intern Med Date: 2013-03-29 Impact factor: 5.128
Authors: Craig Evan Pollack; Amanda L Blackford; Nancy L Schoenborn; Cynthia M Boyd; Kimberly S Peairs; Eva H DuGoff Journal: J Am Geriatr Soc Date: 2016-04-30 Impact factor: 5.562